There is strong evidence that lower than usual targets are beneficial in renal diseases, but especially in those associated with significant proteinuria. Any limits set are arbitrary, but for example, the current SIGN and NICE guideline levels are:

ACE inhibitors or ARBs should be included in:

The previous UK CKD guidelines and some US guidance recommended slightly lower targets, and some nephrologists favour these:

ACE inhibitors are proven to be particularly effective at protecting renal function in patients with proteinuria. A2R antagonists are likely to be equally effective. Non-dihydropyridine calcium antagonists (verapamil, diltiazem) have some theoretical (not proven) advantage if patients cannot tolerate ACEI or A2R blockade.

Blood pressure targets

Should be individualised, as patients have different circumstances.  Benefits from blood pressure reduction do not seem to have age limits, but younger patients might be treated more aggressively as their lifetime risk of end organ damage is greater.

It is sometimes useful to consider average blood pressure at different ages - although it must be noted that there is no evidence to support using these as therapeutic targets.  Figures are from Scotland, 1998.

 
Age
18-24
25-34
35-44
45-54
55-64
65-74
MALE
Systolic
125
128
128
134
141
145
 
Diastolic
62
69
74
79
80
78
FEMALE
Systolic
117
117
121
130
139
149
 
Diastolic
62
66
70
73
74
73

 

Blood pressure in children - we need a nice chart, and will try to make one, but at the foot of the page are a couple of places you can go to find tables. 

 

Blood pressure and proteinuria

 Lowering blood pressure can reduce proteinuria. ACE inhibitors and ARBs achieve greater lowering of proteinuria than other first-line hypotensive agents.

Other proteinuria-reducing strategies are mentioned on the proteinuria page. 

 

Patient information

High blood pressure and kidney disease from EdRenINFO

 

Downloads 

 

 

Arteriography and angioplasty << >> Coding (EDTA-ERA codes)